Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

EVMN

Evommune Inc

Nov 06 • 02:16PM ET

18.73

+2.73 17.06 %

Healthcare • Biotechnology • USA • NYSE

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	13.25M	Perf Week	-
Market Cap	-	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-
Book/sh	-12.93	P/C	-	EPS next 5Y	-	ROE	-	52W High	- -	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	- -	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	3.47	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.40	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	9.40	EPS Q/Q	-	SMA20	0.00%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	0.00%	Rel Volume	-	Prev Close	16.00
Employees	41	LT Debt/Eq	-	Earnings	-	SMA200	0.00%	Avg Volume	-	Price	18.73
IPO	Nov 06, 2025	Option/Short	No / No	EPS/Sales Surpr.	- -	Trades		Volume	1,815,824	Change	17.06%

Today 08:55AM	NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading (PR Newswire)
Nov-05-25 07:45PM	Evommune Announces Pricing of its Initial Public Offering (PR Newswire)

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

open in yahoo | open in reuters | open in marketwatch | open in google

EVMN

Evommune Inc

Upgrade your FINVIZ experience